Lipocine Inc (LPCN)

Etorro trading 970x250

About Lipocine Inc

Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company’s pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase II Clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH); TLANDO XR, an oral prodrug of testosterone for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, an oral prodrug of bioidentical testosterone that has completed phase I clinical trial for the treatment of NASH cirrhosis; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah. Address: 675 Arapeen Drive, Salt Lake City, UT, United States, 84108

Lipocine Inc News and around…

Latest news about Lipocine Inc (LPCN) common stock and company :

12 Health Care Stocks Moving In Tuesday's After-Market Session
19 Oct, 2021 FinancialContent

Gainers Sesen Bio (NASDAQ:SESN) stock moved upwards by 17.82% to $1.19 during Tuesday's after-market session. This security traded ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
19 Oct, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! It's time to get right back into investing with a look at the biggest pre-market stock movers for Tuesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

18 Stocks Moving in Tuesday's Pre-Market Session
19 Oct, 2021 FinancialContent

Gainers Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) rose 26.1% to $2.03 in pre-market trading after surging 18% on ...

Lipocine, Antares Ink Licensing Pact For Testosterone Replacement Therapy In US
18 Oct, 2021 FinancialContent

Lipocine Inc(NASDAQ: LPCN) hasentered into an exclusive licensing agreementwithAntares Pharma ...

Penny Stocks To Watch Today As Buying Drives ADMP, IO, LPCN & Others
18 Oct, 2021 FinancialContent
Lipocine And Antares Pharma Enter Into U.S. Licensing Agreement To Commercialize TLANDO®
18 Oct, 2021 Yahoo! Finance

Under the terms of Agreement Lipocine to receive:

Best Penny Stocks To Buy This Week? 10 With Potential Biotech Catalysts
10 Oct, 2021 FinancialContent
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
08 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
07 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
06 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Lipocine to Present at The H.C. Wainwright 5th Annual NASH Investor Conference
05 Oct, 2021 Yahoo! Finance

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the H.C. Wainwright 5th Annual NASH Investor Conference being held virtually on October 12, 2021.

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
28 Sep, 2021 FinancialContent

Gainers Sonoma Pharmaceuticals (NASDAQ:SNOA) shares increased by 70.28% to $9.11 during Tuesday's pre-market ...

Lipocine Announces FDA Affirmation Of Class 1 NDA Resubmission For TLANDO®
28 Sep, 2021 Yahoo! Finance

Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the U.S. Food and Drug Administration ("FDA") has affirmed the resubmission of its New Drug Application ("NDA") for TLANDO®, its oral testosterone product, will be a Class 1 resubmission. A Class 1 NDA resubmission includes a two-month FDA review goal period. The FDA granted tentative approval to TLANDO in adult males indicated for conditions associated with a de

Lipocine to Present at The Cantor Fitzgerald Virtual Global Healthcare Conference
20 Sep, 2021 Yahoo! Finance

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the Cantor Fitzgerald Virtual Global Healthcare Conference. The conference will be held virtually. Presentation details are below.

Lipocine to Present at The H.C. Wainwright 23rd Annual Global Investment Conference
01 Sep, 2021 Yahoo! Finance

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021.

LPCN: Liver Biopsy Results
31 Aug, 2021 Yahoo! Finance

By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT LiFT Liver Biopsy Results On August 25 th , 2021 Lipocine (NASDAQ:LPCN) released liver biopsy results for its Phase II LiFT study in NASH. LiFT , or Liver Fat Intervention with Oral Testosterone, is a Phase II clinical study designed to evaluate LPCN 1144 oral testosterone in men with biopsy-confirmed NASH. Primary endpoint

Top Reddit Penny Stocks to Watch in September 2021
27 Aug, 2021 FinancialContent
Top Penny Stocks Analysts Say To Buy, Targets Up To 200% Right Now
26 Aug, 2021 FinancialContent
Lipocine Meets Resolution Regulatory Endpoint In Mid-Stage NASH Trial
25 Aug, 2021 FinancialContent

Lipocine Inc(NASDAQ: LPCN) hasannounced topline 36-week resultsfrom its Phase 2 proof of conceptLiFTstudy ...

The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug
25 Aug, 2021 FinancialContent

ere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Lipocine's LPCN 1144 Met Non-Alcoholic Steatohepatitis ("NASH") Resolution Regulatory Endpoint in Phase 2 LiFT Study
25 Aug, 2021 Yahoo! Finance

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced positive topline 36-week results from its Phase 2 proof of concept LiFT ("Liver Fat intervention with oral Testosterone") clinical study, NCT04134091, investigating LPCN 1144 in men with biopsy-confirmed NASH. Currently, there are no approved treatments for NASH, a leading cause of liver failure and liver transplantation globally. LPCN 1144 comprises an orally de

LPCN: New Candidate in Postpartum Depression
09 Aug, 2021 Yahoo! Finance

By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT Second Quarter 2021 Financial and Operational Results On August 5 th , 2021 Lipocine (NASDAQ:LPCN) filed its Form 10-Q and posted its earnings release for the three month period ending June 30, 2021. Highlights for the second quarter 2021 and to-date include: ➢ Summary judgment in patent infringement lawsuit – May 2021 ➢ IND

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2021
05 Aug, 2021 Yahoo! Finance

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial results for the second quarter ended June 30, 2021, and provided a corporate update.

Clarus Therapeutics Announces Comprehensive Settlement of Patent Litigation With Lipocine
15 Jul, 2021 FinancialContent

Clarus Therapeutics Inc. ("Clarus") and Lipocine, Inc. (“Lipocine”) agree to resolve all outstanding claims between the companies in the on-going intellectual property litigation (U. S. District Court for the District of Delaware) and patent interference (U. S. Patent & Trademark Office; USPTO) at no cost to Clarus.

The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
15 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

22 Stocks Moving in Thursday's Pre-Market Session
15 Jul, 2021 FinancialContent

Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) shares rose 63.2% to $8.03 in pre-market trading after jumping around ...

Lipocine Stock Jumps On Litigation Settlement With Clarus Therapeutics
15 Jul, 2021 FinancialContent

Lipocine Inc(NASDAQ: LPCN)has entered into a settlement and license agreementwithClarus Therapeuticsto ...

Lipocine Announces Settlement With Clarus Therapeutics
14 Jul, 2021 Yahoo! Finance

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has entered into a global settlement and license agreement with Clarus Therapeutics Inc. ("Clarus") to resolve all outstanding claims in the on-going intellectual property litigation between the two companies as well as the on-going interference proceeding between the two companies.

Lipocine To Present At The Ladenburg Thalmann Healthcare Conference
06 Jul, 2021 Yahoo! Finance

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the Ladenburg Thalmann Healthcare Conference. The conference will be held virtually. Presentation details are below.

Benzinga's Top Ratings Upgrades, Downgrades For June 24, 2021
24 Jun, 2021 FinancialContent

Upgrades Zelman upgraded the previous rating for Armstrong World Industries Inc (NYSE:AWI) from Hold to Buy. For the ...

Lipocine Inc (LPCN) is a NASDAQ Common Stock listed in , ,

970x250